ERVW-1 and amyotrophic lateral sclerosis: Currently, the anti-HERV-K-env mAb developed is advancing through preclinical validation, and its future clinical trials will be critical to determine its therapeutic efficacy, safety profile, and long-term benefits in ALS patients [53].